论文部分内容阅读
Champlin等报导用抗胸腺细胞球蛋白(ATG) 治疗的中度或重度再生障碍性贫血患者近半数有血液学和临床明显改善,因此进一步支持免疫调节异常可能在再障的发病机制中起作用。据此,作者提出了对常规治疗效果差或无效及不宜作骨髓移殖的患者,可适当选用ATG的免疫抑制治疗。但是,ATG除有明显毒性之外,可对整个胸腺依赖型淋巴细胞群起作用,而无任何T细胞亚群选择性。另一方面,已知在再生障碍性贫血的发病机制中可出现不同的免疫功能紊乱,因此,不同的辅助性或抑制性淋巴细胞亚群可累
Champlin et al. Reported that nearly half of patients with moderate or severe aplastic anemia treated with anti-thymocyte globulin (ATG) had significant hematological and clinical improvement. Therefore, further support for abnormalities in immune regulation may play a role in the pathogenesis of aplastic anemia. Accordingly, the authors put forward the conventional treatment of poor or ineffective and should not be used in patients with bone marrow transplantation, may be appropriate to use ATG immunosuppressive therapy. However, ATG plays a role in the entire thymus-dependent lymphocyte population without any significant toxicity, without any T-cell subsets selectivity. On the other hand, it is known that different immune dysfunctions may occur in the pathogenesis of aplastic anemia, and therefore, different helper or inhibitory lymphocyte subsets may accumulate